



## LJMU Research Online

**McLaughlin, G, Morris, N, Kavanagh, PV, Power, JD, Twamley, B, O'Brien, J, Talbot, B, Dowling, G and Brandt, SD**

**The synthesis and characterization of the 'research chemical' N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-3-(4-fluorophenyl)-1H-pyrazole-5-carboxamide (3,5-AB-CHMFUPPYCA) and differentiation from its 5,3-regioisomer.**

<http://researchonline.ljmu.ac.uk/id/eprint/3149/>

### Article

**Citation** (please note it is advisable to refer to the publisher's version if you intend to cite from this work)

**McLaughlin, G, Morris, N, Kavanagh, PV, Power, JD, Twamley, B, O'Brien, J, Talbot, B, Dowling, G and Brandt, SD (2015) The synthesis and characterization of the 'research chemical' N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-3-(4-fluorophenyl)-1H-pyrazole-5-carboxamide**

LJMU has developed [LJMU Research Online](#) for users to access the research output of the University more effectively. Copyright © and Moral Rights for the papers on this site are retained by the individual authors and/or other copyright owners. Users may download and/or print one copy of any article(s) in LJMU Research Online to facilitate their private study or for non-commercial research. You may not engage in further distribution of the material or use it for any profit-making activities or any commercial gain.

The version presented here may differ from the published version or from the version of the record. Please see the repository URL above for details on accessing the published version and note that access may require a subscription.

For more information please contact [researchonline@ljmu.ac.uk](mailto:researchonline@ljmu.ac.uk)

<http://researchonline.ljmu.ac.uk/>





Accepted manuscript before final correction

**The synthesis and characterization of the 'research chemical' N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-3-(4-fluorophenyl)-1H-pyrazole-5-carboxamide (3,5-AB-CHMFUPPYCA) and differentiation from its 5,3-regioisomer.**

Journal:	<i>Drug Testing and Analysis</i>
Manuscript ID:	DTA-15-0206.R1
Wiley - Manuscript type:	Research Article
Date Submitted by the Author:	n/a
Complete List of Authors:	McLaughlin, Gavin; Athlone Institute of Technology, Life and Physical Sciences; Trinity College, Pharmacology and Therapeutics Morris, Noreen; Athlone Institute of Technology, Life and Physical Sciences Kavanagh, Pierce; Trinity College, Pharmacology and Therapeutics Power, John; Trinity College, Pharmacology and Therapeutics Twamley, Brendan; Trinity College, School of Chemistry O'Brien, John; Trinity College, School of Chemistry Talbot, Brian; Trinity College, School of Pharmacy and Pharmaceutical Sciences Dowling, Geraldine; The State Laboratory, Brandt, Simon; Liverpool John Moores University, School of Pharmacy and Biomolecular Sciences
Keywords:	New Psychoactive Substances, Synthetic Cannabinoids, AB-CHMFUPPYCA isomers, Pyrazole-carboxamide derivatives
Abstract:	This study presents the identification of N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-3-(4-fluorophenyl)-1H-pyrazole-5-carboxamide that was termed 3,5-AB-CHMFUPPYCA. This compound was obtained from a UK-based Internet vendor, who erroneously advertised this 'research chemical' as AZ-037 and which would have been associated with (S)-N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(5-fluoropentyl)-5-(4-fluorophenyl)-1H-pyrazole-3-carboxamide. The presence of the pyrazole core indicates a bioisosteric replacement of an indazole ring that is frequently associated with synthetic cannabinoids of the "PINACA", "FUBINACA" and "CHMINACA" series. The pyrazole ring system present in 3,5-AB-CHMFUPPYCA gives rise to the regioisomer N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-5-(4-fluorophenyl)-1H-pyrazole-3-carboxamide (named 5,3-AB-CHMFUPPYCA) and both isomers were synthesized using two specific routes which supported the correct identification of the 'research chemical' as 3,5-AB-CHMFUPPYCA. Both isomers could be conveniently differentiated. Interestingly, a route specific chlorine-containing by-product also was observed during the synthesis of 3,5-AB-CHMFUPPYCA and identified as N-(1-amino-3-methyl-1-oxobutan-2-yl)-4-chloro-1-

(cyclohexylmethyl)-3-(4-fluorophenyl)-1H-pyrazole-5-carboxamide. An extensive analytical characterization included chromatographic, spectroscopic, mass spectrometric platforms as well as crystal structure analysis. The syntheses and analytical characterizations of both AB-CHMFUPPYCA isomers are reported for the first time and it serves as a reminder that the possibility of mislabeling of 'research chemicals' cannot be excluded. The pharmacological activities of both AB-CHMFUPPYCA isomers remain to be explored.

SCHOLARONE™  
Manuscripts

For Peer Review

1  
2  
3 **The synthesis and characterization of the ‘research chemical’ *N*-(1-**  
4 **amino-3-methyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-3-(4-fluorophenyl)**  
5 **-1*H*-pyrazole-5-carboxamide (3,5-AB-CHMFUPPYCA) and differentiation**  
6 **from its 5,3-regioisomer.**  
7  
8

9  
10  
11 Gavin McLaughlin, <sup>a,b\*</sup> Noreen Morris, <sup>a</sup> Pierce V. Kavanagh, <sup>b</sup> John D. Power,  
12 <sup>b,c</sup> Brendan Twamley <sup>d</sup> John O’Brien, <sup>d</sup> Brian Talbot, <sup>e</sup> Geraldine Dowling, <sup>f</sup>  
13 and Simon D. Brandt <sup>g</sup>  
14  
15

16  
17  
18  
19 <sup>a</sup> *Department of Life and Physical Sciences, School of Science, Athlone Institute of*  
20 *Technology, Dublin Road, Westmeath, Ireland*  
21

22  
23 <sup>b</sup> *Department of Pharmacology and Therapeutics, School of Medicine, Trinity Centre for*  
24 *Health Sciences, St. James’s Hospital, Dublin 8, Ireland*  
25

26  
27 <sup>c</sup> *Forensic Science Laboratory, Garda HQ, Dublin 8, Ireland*  
28

29  
30 <sup>d</sup> *School of Chemistry, Trinity College Dublin, Dublin 2, Ireland*  
31

32  
33 <sup>e</sup> *School of Pharmacy and Pharmaceutical Sciences, Trinity College Dublin, Dublin 2, Ireland*  
34

35  
36 <sup>f</sup> *The State Laboratory, Backweston Laboratory Complex, Young’s Cross, Celbridge, Kildare,*  
37 *Ireland*  
38

39  
40 <sup>g</sup> *School of Pharmacy and Biomolecular Sciences, Liverpool John Moores University, Byrom*  
41 *Street, Liverpool L3 3AF, UK*  
42

43  
44 \*Correspondence to: Gavin McLaughlin, Department of Pharmacology and  
45 Therapeutics, School of Medicine, Trinity Centre for Health Sciences, St. James’s  
46 Hospital, Dublin 8, Ireland. Email: gavinmclaughlin@research.ait.ie or  
47 gmclaug@tcd.ie  
48  
49

50  
51  
52  
53 **Running title:** Syntheses and characterization of AB-CHMFUPPYCA isomers  
54

55 **Keywords:** New Psychoactive Substances. Synthetic Cannabinoids. AB-  
56 CHMFUPPYCA isomers. Pyrazole-carboxamide derivatives.  
57  
58  
59  
60

## Abstract

This study presents the identification of *N*-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-3-(4-fluorophenyl)-1*H*-pyrazole-5-carboxamide that was termed 3,5-AB-CHMFUPPYCA. This compound was obtained from a UK-based Internet vendor, who erroneously advertised this 'research chemical' as AZ-037 and which would have been associated with (*S*)-*N*-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(5-fluoropentyl)-5-(4-fluorophenyl)-1*H*-pyrazole-3-carboxamide. The presence of the pyrazole core indicates a bioisosteric replacement of an indazole ring that is frequently associated with synthetic cannabinoids of the "PINACA", "FUBINACA" and "CHMINACA" series. The pyrazole ring system present in 3,5-AB-CHMFUPPYCA gives rise to the regioisomer *N*-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-5-(4-fluorophenyl)-1*H*-pyrazole-3-carboxamide (named 5,3-AB-CHMFUPPYCA) and both isomers were synthesized using two specific routes which supported the correct identification of the 'research chemical' as 3,5-AB-CHMFUPPYCA. Both isomers could be conveniently differentiated. Interestingly, a route specific chlorine-containing by-product also was observed during the synthesis of 3,5-AB-CHMFUPPYCA and identified as *N*-(1-amino-3-methyl-1-oxobutan-2-yl)-4-chloro-1-(cyclohexylmethyl)-3-(4-fluorophenyl)-1*H*-pyrazole-5-carboxamide. An extensive analytical characterization included chromatographic, spectroscopic, mass spectrometric platforms as well as crystal structure analysis. The syntheses and analytical characterizations of both AB-CHMFUPPYCA isomers are reported for the first time and it serves as a reminder that the possibility of mislabeling of 'research chemicals' cannot be excluded. The pharmacological activities of both AB-CHMFUPPYCA isomers remain to be explored.

## Introduction

Over the past decade, the phenomenon linked to new psychoactive substances (NPS) has attracted great interest from various communities and stakeholders that are concerned with public health, law enforcement and a range of fundamental sciences. The diversity of compounds that show, or are suspected to show, psychoactive properties in humans and that are made available to the general public by various routes include synthetic replacements for controlled substances, designer drugs in the traditional sense, regulated and unregulated medicinal products and derivatives of various biological activities developed by the pharmaceutical industry.<sup>[1]</sup> The European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) is currently monitoring over 450 NPS via the European Union (EU) Early warning system (EWS) on NPS and it has become clear that the number of notified synthetic cannabinoids has risen to over 130.<sup>[2,3]</sup> The number of substances, the diversity in their chemical structure and the rate of their emergence make synthetic cannabinoids one of the largest family of NPS monitored at European level and it is equally obvious that this is a more widespread phenomenon (e.g.<sup>[4,5]</sup>). A number of recently occurring synthetic cannabinoids included the emergence of substituted indazole core structures that carry a valinamide component. Examples may be found in the so-called "PINACA", "FUBINACA" and "CHMINACA" series (Figure 1A) and a range of studies have been published<sup>[6-20]</sup> in addition to recent developments in the United States of America where some of these newly emerging substances were subjected to temporary placement into Schedule 1.<sup>[21,22]</sup>

A more recent example in which the indazole core is replaced by a pyrazole ring, thus creating a bioisosteric system that mimics the indazole ring system, can be found in (S)-N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(5-fluoropentyl)-5-(4-fluorophenyl)-1H-pyrazole-3-carboxamide that is currently advertised by a number of Internet retailers as the synthetic cannabinoid AZ-037. Following previously suggested conventions in naming structurally related substances, the name 5,3-5F-AB-FUPPYCA is suggested (Figure 1B). Although the identification of the structurally related 3,5-5F-ADB-FUPPYCA has been recently reported<sup>[23]</sup> (Figure 1B), detailed data on AZ-037 have not yet been described. The present study describes the characterization of a sample advertised as AZ-037 that was donated in January 2015 by an online retailer based in the United Kingdom. This sample was subjected to analytical characterization by gas chromatography (GC) and high performance liquid

1  
2  
3 chromatography (HPLC) coupled to various forms of mass spectrometry (MS) and  
4 nuclear magnetic resonance spectroscopy (NMR). These investigations revealed that  
5 the material was inconsistent with the structural features associated with AZ-037.  
6 Instead, the substance was characterized as *N*-(1-amino-3-methyl-1-oxobutan-2-yl)-  
7 1-(cyclohexylmethyl)-3-(4-fluorophenyl)-1*H*-pyrazole-5-carboxamide, which was  
8 termed 3,5-AB-CHMFUPPYCA. Incidentally, the detection of this compound has just  
9 been reported to the EMCDDA by members of the EU EWS on NPS, and was  
10 termed AB-CHMFUPPYCA.<sup>[24]</sup> Further confirmation was obtained from organic  
11 synthesis of this substance along with its alternative regioisomer *N*-(1-amino-3-  
12 methyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-5-(4-fluorophenyl)-1*H*-pyrazole-3-  
13 carboxamide (5,3-AB-CHMFUPPYCA) that arises from presence of the pyrazole core  
14 structure. Both isomers were synthesized using two specific routes and subjected to  
15 extensive analytical characterization using chromatographic, spectroscopic, mass  
16 spectrometric platforms as well as crystal structure analysis. The 'research chemical'  
17 obtained from the Internet vendor was consistent with a compound isolated from  
18 plant material in Japan where it was termed AB-CHFUPPYCA although further  
19 confirmation by synthesis of the two possible isomers was not obtained.<sup>[25]</sup>  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32

## 33 Experimental

### 34 *Reagents and standards*

35  
36  
37 All reagents and dry solvents used in the syntheses were obtained from Sigma  
38 Aldrich Ltd. (Arklow, Ireland). LC-MS grade solvents were obtained from Fisher  
39 Scientific (Dublin, Ireland). A sample, advertised as AZ-037, was donated by a UK  
40 based 'research chemical' vendor in January 2015.  
41  
42  
43  
44  
45

### 46 *Syntheses*

#### 47 *Methyl 4-(4-fluorophenyl)-2,4-dioxobutanoate*

48  
49  
50 Potassium *tert*-butoxide (11.20 g, 100 mmol) was added to a solution of dimethyl  
51 oxalate (11.80 g, 100 mmol) in tetrahydrofuran (75 mL). The mixture was stirred at  
52 room temperature for 30 min. A solution of 4-fluoroacetophenone (6.4 g, 50 mmol) in  
53 tetrahydrofuran (25 mL) was added and stirring was continued for 1 h. The reaction  
54 mixture was then added to 0.5 M aqueous hydrochloric acid (600 mL) and the  
55  
56  
57  
58  
59  
60



precipitated solid was collected by filtration to afford a light yellow solid (9.54 g, 43 mmol, 86 %): ESI-HRMS  $m/z$  found 225.0568 ( $m/z$  theor. for M+H, C<sub>11</sub>H<sub>10</sub>O<sub>4</sub>F, 225.0558). <sup>1</sup>H NMR (d<sub>6</sub>-CDCl<sub>3</sub>) δ 7.77-7.69 (m, 2H, 2 x Ar-CH), 7.23-7.14 (m, 2H, 2 x Ar-CH), 7.05 (s, 1H, OH), 3.96 (d,  $J$  = 1.2 Hz, 3H), <sup>13</sup>C NMR (d<sub>6</sub>-CDCl<sub>3</sub>) δ 189.71 (C=O), 168.67-167.05 (Ar-CF), 165.35 (C(OH)), 162.53 (C=O), 131.27 (Ar-C), 130.50 (Ar-CH), 116.34 (Ar-CH), 53.20 (CH<sub>3</sub>), <sup>19</sup>F (d<sub>6</sub>-CDCl<sub>3</sub>) δ -103.91 ppm.

#### *Methyl 5-(4-fluorophenyl)-1H-pyrazole-3-carboxylate*

A mixture of methyl 4-(4-fluorophenyl)-2,4-dioxobutanoate (4.48 g, 20 mmol) and hydrazine hydrate (1.10 g, 22 mmol) in acetic acid (20 mL) was heated (oil bath at 100 °C) for 2 h. The mixture was allowed to cool to room temperature and the product was collected by filtration to afford colorless crystals that were used without further purification (3.08 g, 14.0 mmol, 70 %): ESI-HRMS  $m/z$  found 221.0725 ( $m/z$  theor. for M+H, C<sub>11</sub>H<sub>10</sub>O<sub>2</sub>N<sub>2</sub>F, 221.0721).

#### *Cyclohexylmethyl)hydrazine trifluoroacetate salt*

A mixture of *tert*-butyl carbazate (5.89 g, 44.6 mmol) and cyclohexanecarboxaldehyde (5.00 g, 44.6 mmol) in methanol (140 mL) was stirred at room temperature for 1 h. The solution was then evaporated to dryness. Aqueous 50 % v/v aqueous acetic acid (125 mL) was added and, with constant mixing, sodium cyanoborohydride (2.80 g, 44.6 mmol) was added. The mixture was stirred for 2 h at room temperature, diluted with water, neutralized with sodium hydroxide and extracted with dichloromethane. Drying (anhydrous magnesium sulfate) and removal of the solvent afforded a colorless oil, which was dissolved in a mixture of dichloromethane (30 mL) and trifluoroacetic acid (30 mL). The mixture was stirred for 1 h at room temperature and the volatiles were removed under vacuum to afford a light brown, viscous oil (15.27 g which was used without further purification).

*N*-(1-Amino-3-methyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-5-(4-fluorophenyl)-1H-pyrazole-3-carboxamide and *N*-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-3-(4-fluorophenyl)-1H-pyrazole-5-carboxamide (5,3-AB-CHMFUPPYCA) (Figure 2A)

1  
2  
3 A mixture of crude cyclohexylmethyl)hydrazine trifluoroacetate (2.00 g) and methyl 4-  
4 (4-fluorophenyl)-2,4-dioxobutanoate (1.12 g, 10 mmol) in methanol (20 mL) was  
5 refluxed for 3 h. The mixture was allowed to cool to room temperature, the volatiles  
6 removed under vacuum and the residue partitioned between aqueous sodium  
7 carbonate and dichloromethane. Drying (anhydrous magnesium sulfate) followed by  
8 solvent removal gave a yellow oil. Tetrahydrofuran (20 mL), water (10 mL) and  
9 lithium hydroxide (2.00 g) were added. The mixture was heated (oil bath at 80 °C) for  
10 2 h and then allowed to stir overnight at room temperature. The mixture was diluted  
11 with water, washed with diethyl ether, made acidic (concentrated aqueous  
12 hydrochloric acid) and extracted with dichloromethane. Drying (anhydrous  
13 magnesium sulfate) and removal of the solvent afforded light a light yellow solid (936  
14 mg). Thionyl chloride (5 mL) was added to the solid (836 mg) and the mixture was  
15 refluxed for 1 hr. The volatiles were then removed under vacuum. *N,N*-  
16 Dimethylformamide (5 mL), *L*-valinamide hydrochloride (0.50 g, 3.3 mmol) and *N,N*-  
17 diisopropylethylamine (3 mL) were added, and the mixture was stirred at room  
18 temperature for 4 h. The mixture was diluted with water and extracted with  
19 dichloromethane. Drying (anhydrous magnesium sulfate) and removal of the solvent  
20 afforded a light a brown oil (689 mg). This was purified by preparative thin layer  
21 chromatography (silica gel; ethyl acetate/hexane, 9/1; 2 runs) to afford a beige solid  
22 (74 mg, 0.19 mmol, 2.1 % from methyl 4-(4-fluorophenyl)-2,4-dioxobutanoate): ESI-  
23 HRMS *m/z* found 401.2346 (*m/z* theor. for M+H, C<sub>22</sub>H<sub>30</sub>O<sub>2</sub>N<sub>4</sub>F, 401.2347); Melting  
24 point: 58-62 °C. <sup>1</sup>H NMR (d<sub>6</sub>-DMSO) δ 7.63 (s; 1 H; one H from NH<sub>2</sub>), 7.82-7.85 (m; 3  
25 H; Ar H and one H from NH<sub>2</sub>), 7.36 (t; *J* = 8.8 Hz; 2 H; Ar H), 6.73 (s; 1 H; pyrazole H),  
26 4.36 (dd; *J* = 9.0, 6.3 Hz; NH-CH-CO), 4.02 (d; *J* = 7.2 Hz; 2 H; CyCH<sub>2</sub>N), 2.03-2.10  
27 (m; 1 H; CH(CH<sub>3</sub>)<sub>2</sub>), 1.71-1.79 (m; 1 H; cyclohexyl H), 1.49-1.59 (m; 3 H; cyclohexyl  
28 H), 1.34-1.42 (m; 2 H; cyclohexyl H), 1.02-1.14 (m; 3 H; cyclohexyl H), 0.92 (d; *J* =  
29 6.8 Hz; 3 H; CH<sub>3</sub>), 0.88 (d; *J* = 6.8 Hz; 3 H; CH<sub>3</sub>) and 0.70-0.8 (m; 2 H; cyclohexyl H)  
30 ppm; <sup>13</sup>C NMR (d<sub>6</sub>-DMSO) δ 172.54 (C=O), 162.26 (d; <sup>1</sup>*J*<sub>CF</sub> = 245 Hz; Ar C), 160.63  
31 (C=O), 144.95 (pyrazole C), 144.21 (pyrazole C), 131.23 (d; <sup>3</sup>*J*<sub>CF</sub> = 8 Hz; Ar CH),  
32 126.19 (Ar C), 115.86 (d; <sup>2</sup>*J*<sub>CF</sub> = 22 Hz; Ar CH), 106.31 (pyrazole CH), 56.78 (CO-CH-  
33 NH), 55.34 (CyCH<sub>2</sub>N), 38.09 (cyclohexyl CH), 30.53 (CH(CH<sub>3</sub>)<sub>2</sub>), 29.72/29.67 (2 x  
34 cyclohexyl CH<sub>2</sub>), 25.67 (cyclohexyl CH<sub>2</sub>), 24.98/24.95 (2 x cyclohexyl CH<sub>2</sub>), 19.29  
35 (CH<sub>3</sub>) and 17.92 (CH<sub>3</sub>) ppm; <sup>19</sup>F NMR (d<sub>6</sub>-DMSO) δ -112.98 ppm.

36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55 *N*-(1-Amino-3-methyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-5-(4-fluorophenyl)-1H-  
56 pyrazole-3-carboxamide and *N*-(1-amino-3-methyl-1-oxobutan-2-yl)-1-  
57  
58  
59  
60

(cyclohexylmethyl)-3-(4-fluorophenyl)-1H-pyrazole-5-carboxamide (3,5-AB-CHMFUPPYCA) (Figure 2B)

A mixture of methyl 5-(4-fluorophenyl)-1H-pyrazole-3-carboxylate (250 mg, 1.14 mmol), (bromomethyl)cyclohexane (404 mg, 2.28 mmol), cesium carbonate (371 mg, 2.28 mmol) in dimethylformamide (3 mL) was stirred overnight at room temperature. The mixture was then diluted with saturated aqueous ammonium chloride solution and extracted with dichloromethane. Drying (anhydrous magnesium sulfate) and removal of the solvent afforded a colorless oil (428 mg). Lithium hydroxide (480 mg) and tetrahydrofuran (5 mL) were added, the mixture refluxed for 6 h and then allowed to stir overnight at room temperature. The mixture was diluted with water, washed with diethyl ether, made acidic (conc. aqueous hydrochloric acid) and extracted with dichloromethane. Drying (anhydrous magnesium sulfate) and removal of the solvent afforded light a colorless solid (230 mg, 0.76 mmol). Thionyl chloride (3 mL) was added to the solid and the mixture was refluxed for 1 h. The volatiles were then removed under vacuum. *N,N*-Dimethylformamide (2.5 mL), *L*-valinamide hydrochloride (304 mg, 2 mmol) and *N,N*-diisopropylethylamine (1 mL) were added, and the mixture was stirred at room temperature for 4 h. This was then diluted with water and extracted with dichloromethane. Drying (anhydrous magnesium sulfate) and removal of the solvent afforded a beige solid (257 mg). This was purified by preparative thin layer chromatography (silica gel; ethyl acetate/hexane, 9/1) to afford an almost colorless solid (115 mg, 0.29 mmol, 25 % from methyl 5-(4-fluorophenyl)-1H-pyrazole-3-carboxylate). This was recrystallized (ethanol) to give a colorless solid (49 mg): ESI-HRMS *m/z* found 401.2344 (*m/z* theor. for M+H, C<sub>22</sub>H<sub>30</sub>O<sub>2</sub>N<sub>4</sub>F, 401.2347); Melting point: 172-178 °C. <sup>1</sup>H NMR (d<sub>6</sub>-DMSO) δ 8.20 (d; *J* = 8.8 Hz; 1 H; NH), 7.82-7.85 (m; 2 H; Ar H), 7.48 (s; 1 H; one H from NH<sub>2</sub>), 7.40 (s; 1 H; pyrazole H), 7.27 (tr; *J* = 8.9 Hz; 2 H; Ar H), 7.13 (s; 1 H; one H from NH<sub>2</sub>), 4.37 (dd; *J* = 7.2, 2.4 Hz; 2 H; CyCH<sub>2</sub>N), 4.26 (dd; *J* = 8.4, 8.1 Hz; NH-CH<sub>2</sub>-CO), 2.07-2.14 (m; 1 H; CH(CH<sub>3</sub>)<sub>2</sub>), 1.77-1.85 (m; 1 H; cyclohexyl H), 1.47-1.67 (m; 5 H; cyclohexyl H), 1.10-1.17 (m; 3 H; cyclohexyl H) and 0.91-0.99 (m; 8 H; 2 cyclohexyl H and 2 CH<sub>3</sub>) ppm; <sup>13</sup>C NMR (d<sub>6</sub>-DMSO) δ 172.87 (C=O), 161.10 (d; <sup>1</sup>*J*<sub>CF</sub> = 243 Hz; Ar C), 159.71 (C=O), 147.62 (pyrazole C), 137.40 (pyrazole C), 129.64 (Ar C), 127.27 (d; <sup>3</sup>*J*<sub>CF</sub> = 8 Hz; Ar CH), 115.96 (d; <sup>2</sup>*J*<sub>CF</sub> = 21 Hz; Ar CH), 104.84 (pyrazole CH), 58.49 (CO-CH-NH), 56.47 (CyCH<sub>2</sub>N), 39.94 (cyclohexyl CH), 30.35 (CH(CH<sub>3</sub>)<sub>2</sub>), 30.23 (cyclohexyl CH<sub>2</sub>), 26.19 (cyclohexyl CH<sub>2</sub>), 25.50 (cyclohexyl CH<sub>2</sub>), 19.68 (CH<sub>3</sub>) and 18.73 (CH<sub>3</sub>) ppm; <sup>19</sup>F NMR (d<sub>6</sub>-DMSO) δ -115.00 ppm. A sample of the product was recrystallized from ethyl acetate/cyclohexane for x-ray crystallography.

## Instrumentation

### *Liquid chromatography - mass spectrometry*

LC-MS analyses, equipped with an electrospray ionization source, were performed on an Agilent 1100 LC system. The column (Allure PFP Propyl, 5  $\mu\text{m}$ , 50  $\times$  2.1 mm) was from Restek (Bellefonte, PA, USA) and the aqueous mobile phase A consisted of 0.1% formic acid in water whereas mobile phase B was prepared from 0.1% formic acid in acetonitrile, respectively. The Agilent LC-MSD settings were as follows: positive electrospray mode, capillary voltage 3000 V, drying gas ( $\text{N}_2$ ) 12 L/min at 350  $^\circ\text{C}$ , nebulizer gas ( $\text{N}_2$ ) pressure 60 psi,  $m/z$  50-500, fragmentor voltage either 50 V, 130 V or 150 V. Samples for LC-MS analysis (2  $\mu\text{L}$  injection volume) were dissolved in acetonitrile/water (1:1, containing 0.1% formic acid) at a concentration of 5  $\mu\text{g/mL}$ . The following gradient elution program was used: 0-5 min 12% A and then increased to 35% over 30 min using a linear gradient. The flow rate was 1 mL/min and the column temperature was 30  $^\circ\text{C}$ .

### *Gas chromatography – mass spectrometry*

An Agilent 6980 GC coupled to an Agilent 5973 MSD (HP-5ms column, 30 m  $\times$  0.25 mm  $\times$  0.25  $\mu\text{m}$ ) using helium as the carrier gas at a constant flow of 1 mL/min was employed in splitless mode. Injection port and transfer line temperatures were set at 250  $^\circ\text{C}$  and 280  $^\circ\text{C}$ , respectively. Oven temperature: 150  $^\circ\text{C}$  held for 2 min, ramped at 20  $^\circ\text{C}/\text{min}$  to 300  $^\circ\text{C}$  and held for 10.5 min. The total run time was 20 min. The samples for analysis were dissolved in acetonitrile and the injection volume was 1  $\mu\text{L}$ .

### *X-Ray Crystallography*

Intensity data were collected at 100(2) K using a MiTeGen micromount on a Bruker APEX Duo CCD diffractometer equipped with an Oxford Cobra cryosystem. Data were collected using  $\omega$  and  $\phi$  scans, corrected for Lorentz and polarization effects, and integrated using the Bruker APEX program suite. Structures were solved by direct methods and refined with least squares procedures. All non-hydrogen atoms were refined anisotropically and hydrogen atoms were placed geometrically in the calculated positions using a riding model except for H21, H28a, and H28b which were located and refined.

1  
2  
3  
4 Data collected using Cu K $\alpha$  radiation (1.54178 Å) for a colorless plate crystal 0.26 ×  
5 0.11 × 0.08mm<sup>3</sup>, C<sub>24</sub>H<sub>32</sub>FN<sub>5</sub>O<sub>2</sub>, M = 441.54, Monoclinic, P2<sub>1</sub>, a = 12.1979(5),  
6 b=7.0566(3), c = 14.6230(6)Å,  $\beta$  = 111.6180(10)°, V = 1170.15(8)Å<sup>3</sup>, Z=2,  $\rho$  =  
7 1.253mg/m<sup>3</sup>,  $\mu$  =0.709mm<sup>-1</sup>, Reflections collected 18953 ( $\theta_{\max}$  = 68.49°), independent  
8 reflections 4247,  $R_{(\text{int})}$  = 0.0321, S = 1.025, R1 = 0.0290, wR2 = 0.0753.\* CCDC  
9 deposition number 1405051. (\* R1= $\Sigma||\text{Fo}|-|\text{Fc}|| / \Sigma |\text{Fo}|$  and wR2 =  $\Sigma w(|\text{Fo}|^2-|\text{Fc}|^2)^2 /$   
10  $\Sigma w|\text{Fo}|^2)^{1/2}$ )  
11  
12  
13  
14  
15  
16  
17

### 18 *Nuclear magnetic resonance spectroscopy*

19 Samples were prepared in d<sub>6</sub>-DMSO and <sup>1</sup>H (600 MHz) and <sup>13</sup>C (150 MHz) NMR  
20 spectra were recorded on a Bruker AV600 NMR spectrometer using a 5 mm TCI  
21 cryoprobe. <sup>1</sup>H NMR spectra were referenced to an external TMS reference at  $\delta$  = 0  
22 ppm.  
23  
24  
25  
26

### 27 *High-resolution electrospray mass spectrometry*

28 HR-ESI mass spectra were recorded by direct injection into a LTQ Orbitrap  
29 Discovery (Thermo Fisher, UK). Samples were dissolved in acetonitrile/water  
30 (1:1, containing 0.1% formic acid) and infused at a rate of 5  $\mu$ L/min. Full  
31 accurate high-resolution (30000) mass scans were performed in positive  
32 electrospray mode. Measured accurate masses were within  $\pm$  5ppm of the  
33 theoretical masses. The following conditions were used: drying gas (N<sub>2</sub>) 10000  
34 mL/min, capillary temperature 310 °C, spray voltage 4 V, capillary voltage 22 V and  
35 tube lens 77 V.  
36  
37  
38  
39  
40  
41  
42

## 43 **Results and discussion**

44  
45  
46 The structural diversity associated with substances considered as so-called  
47 synthetic cannabinoids can create challenges to forensic, clinical, law enforcement  
48 and regulatory communities.<sup>[2-5,26-28]</sup> Some of the recently occurring indazole  
49 derivatives (Figure 1A) are based on the patent literature which point towards  
50 appreciable CB<sub>1</sub> receptor affinity and [<sup>35</sup>S]GTP $\gamma$ S activity<sup>[29,30]</sup> but others remain to  
51 be fully explored to assess the extent to which these substances show  
52 psychopharmacological similarities to compounds present in cannabis. A compound  
53 that appeared to deviate from currently reported core structures, i.e. carrying a  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 pyrazole moiety instead of a more established indole, benzimidazole, pyrrole or  
4 indazole core, has been advertised on a number of 'research chemicals' websites  
5 as AZ-037, which represents (S)-N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(5-  
6 fluoropentyl)-5-(4-fluorophenyl)-1H-pyrazole-3-carboxamide (Figure 1B). Any  
7 information about its psychoactive or pharmacological properties seems to be  
8 currently unavailable although it appears to be advertised as a synthetic  
9 cannabinoid on various websites. The EMCDDA has recently received a notification  
10 on its detection in an EU Member State via the EU EWS on NPS.<sup>[31]</sup>  
11  
12  
13  
14  
15

16  
17 The present investigation was initiated following the donation of a vendor sample to  
18 the authors' laboratories labeled as AZ-037. During initial characterization it was  
19 revealed that the analytical data were inconsistent with the expected structure.  
20 Inspection of the UK-based website also indicated that the suggested IUPAC name  
21 for AZ-037 was also not in agreement with the shown structure. The shown  
22 structure associated with AZ-037 was 1-(5-fluoropentyl)-1H-indole-3-carboxylic acid  
23 8-quinolinyl ester, i.e. commonly referred to as the synthetic cannabinoid 5F-PB-22.  
24 Interestingly, the analytical characterization of a substance very closely related to  
25 AZ-037 has been published recently. In this case, the reported compound was N-  
26 (1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(5-fluoropentyl)-3-(4-fluorophenyl)-  
27 pyrazole-5-carboxamide and the suggested name for this substance is 3,5-5F-ADB-  
28 FUPPYCA (Figure 1B). The presence of the pyrazole ring can give rise to a number  
29 of isomers, which complicates matters significantly and this meant that the  
30 chromatographic separation and characterization of isomers was deemed  
31 necessary. The preparation of both isomers associated with positions 5 and 3  
32 confirmed unambiguously that the sample received from the Internet supplier was  
33 consistent with 3,5-AB-CHMFUPPYCA (Figure 2).  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43

## 44 **Synthesis**

45  
46  
47 Both regioisomers 5,3-AB-CHMFUPPYCA and 3,5-AB-CHMFUPPYCA were  
48 synthesized using two specific routes that are outlined in Figure 2. The synthesis of  
49 5,3-AB-CHMFUPPYCA involved the reaction of methyl 4-(4-fluorophenyl)-2,4-  
50 dioxobutanoate (a) with (cyclohexylmethyl)-hydrazine (b), which gave rise to the  
51 pyrazole intermediate (c). This intermediate was then reacted with lithium  
52 hydroxide, which provided the carboxylic acid species (d). This entity was reacted  
53 with thionyl chloride and subsequently N,N-dimethylformamide, L-valinamide  
54 hydrochloride and N,N-diisopropylethylamine to yield the 5,3-AB-CHMFUPPYCA  
55  
56  
57  
58  
59  
60



1  
2  
3 product (Figure 2A). The preparation of 3,5-AB-CHMFUPPYCA involved reacting 5-  
4 (4-fluorophenyl)-1*H*-pyrazole-3-carboxylate (e) with (bromomethyl)-cyclohexane (f)  
5 and cesium carbonate yielding the cyclohexylmethyl intermediate (g). This  
6 intermediate was reacted with lithium hydroxide, which induced the formation of the  
7 carboxylic acid species (h). This entity was reacted with thionyl chloride and  
8 subsequently *N,N*-dimethylformamide, *L*-valinamide hydrochloride and *N,N*-  
9 diisopropylethylamine, which yielded the 3,5-AB-CHMFUPPYCA product (Figure  
10 2B).  
11  
12  
13  
14  
15

16  
17 The structural differences in the regioisomers included the positioning of the  
18 substituents around the pyrazole core, which were dictated by the positioning of the  
19 double bonds within the pyrazole ring structure. In the 5,3-AB-CHMFUPPYCA isomer  
20 (Figure 2A) the 4-fluorophenyl component was attached to position 5 whereas the  
21 secondary carboxamide structure was attached to position 3 of the pyrazole ring. In  
22 case of the 3,5-AB-CHMFUPPYCA isomer, the opposite arrangement was present. A  
23 route specific chlorine containing by-product, *N*-(1-amino-3-methyl-1-oxobutan-2-yl)-  
24 4-chloro-1-(cyclohexylmethyl)-3-(4-fluorophenyl)-1*H*-pyrazole-5-carboxamide, was  
25 encountered during the synthesis of the 3,5-AB-CHMFUPPYCA isomer  
26 (supplemental information) and this was not observed during the preparation of the  
27 regioisomeric form.  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37

#### 38 *Gas chromatography mass spectrometry*

39 Separation of both isomers was successfully achieved using gas chromatography  
40 (GC). The retention times for 5,3-AB-CHMFUPPYCA and 3,5-AB-CHMFUPPYCA  
41 were 14.74 and 15.20 min, respectively, and a comparison with the vendor sample  
42 was in agreement with the identity of the latter (Figure 3A-C). A comparison of both  
43 EI mass spectra also provided sufficient evidence that both isomers could be  
44 differentiated based on fragmentation patterns (Figure 3E-F). In the EI mass spectrum  
45 for 5,3-AB-CHMFUPPYCA, the base peak was observed at *m/z* 285 and indicated  
46 the loss of 115 Da from the parent molecule, which represented the formation of an  
47 oxonium species (Figure 3G). Another dominant peak was observed at *m/z* 356 that  
48 may be described by the loss of formamide from the molecular ion. Another minor  
49 fragment encountered in the EI mass spectrum was *m/z* 189, which might have been  
50 consistent with the loss of cyclohexylmethyl species from the oxonium ion at *m/z* 285.  
51 In the EI mass spectrum of 3,5-AB-CHMFUPPYCA, the base peak was observed at  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  $m/z$  257, which was thought to represent the 1-(cyclohexylmethyl)-3-(4-fluorophenyl)-  
4 1*H*-pyrazole fragment and its formation might have been facilitated by the position of  
5 the double bonds within the pyrazole ring of the 3,5-AB-CHMFUPPYCA isomer  
6 (Figure 3G). The positioning of the double bonds in the pyrazole ring might have  
7 facilitated the formation of a temporary double bond between the nitrogen at position  
8 1 of the pyrazole ring and the carbon at position 5, which might have resulted in the  
9 formation of a thermodynamically stable species (Figure 4). The formation of this  
10 species would not have been possible with the 5,3-AB-CHMFUPPYCA isomer due to  
11 the positioning of the double bonds within the pyrazole ring. Also present in the EI  
12 mass spectrum of the 3,5-AB-CHMFUPPYCA isomer was the detection of the  
13 molecular ion at  $m/z$  400. The fragment at  $m/z$  356 was presumably formed by the  
14 loss of formamide (Figure 3G). The chlorinated by-product formed during the  
15 synthesis of 3,5-AB-CHMFUPPYCA was detected under GC-MS analysis conditions  
16 and a retention time of 16.07 min was obtained for this compound (supplemental  
17 data).

#### 28 *Liquid chromatography mass spectrometry*

30 Analysis of both synthesized isomers and the vendor sample by high performance  
31 liquid chromatography (HPLC) confirmed satisfactory separation. A retention time of  
32 13.41 min was obtained for the 5,3-AB-CHMFUPPYCA isomer, whereas a retention  
33 time of 13.85 min was obtained for the 3,5-AB-CHMFUPPYCA isomer (Figure 5).  
34 The electrospray ionization (ESI) single quadrupole mass spectra obtained from in-  
35 source collision-induced dissociation (CID) of the synthesized regioisomers (150 V  
36 fragmentor voltage) shared similar product ions but key features that allowed for  
37 differentiation between the two substances were also apparent (Figure 6). For  
38 example, the in-source CID spectrum of 5,3-AB-CHMFUPPYCA displayed the  
39 sodiated adduct  $[M + Na]^+$  at  $m/z$  423 as the base peak (Figure 6A), which was not  
40 the case with 3,5-AB-CHMFUPPYCA where the relative abundance was around 40%  
41 (Figure 6B). A major difference, however, was observed in the mass spectrum of 3,5-  
42 AB-CHMFUPPYCA that formed a base peak at  $m/z$  260 and which was absent in the  
43 5,3-AB-CHMFUPPYCA (Figure 6A). Figure 6C shows a proposed mechanism of its  
44 formation that may be rationalized by the loss of 2-cyclohexylacetamide from the  
45 protonated molecule. Product ions common in both spectra included  $m/z$  356 by way  
46 of cleaving formamide from the protonated molecule and the subsequent formation of  
47 the  $m/z$  285 oxonium ion. The  $m/z$  189 ion may have then been formed by the loss of  
48 the cyclohexylmethyl species from the oxonium fragment, resulting in a species with  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



1  
2  
3 chemical formula  $C_{10}H_6FN_2O^+$ . The chlorinated by-product was observed during the  
4 HPLC-ESI-MS analysis of 3,5-AB-CHMFUPPYCA. A retention time of 14.49 min was  
5 obtained for this compound (supplemental data). Analysis by high-resolution mass  
6 spectrometry was employed, which yielded formation of identical product ions for  
7 each isomer (supplemental data).  
8  
9

#### 10 11 12 13 14 *Nuclear magnetic resonance spectrometry*

15  
16 In addition to one-dimensional proton ( $^1H$ ), carbon ( $^{13}C$ ) and fluorine ( $^{19}F$ ) NMR  
17 analyses, the implementation of two-dimensional experiments proved helpful for the  
18 characterization of both isomers and the vendor sample. For example, in the case of  
19 5,3-AB-CHMFUPPYCA, heteronuclear multiple-bond correlation (HMBC)  
20 experiments revealed a 3-bond  $^1H/^{13}C$  correlation between the respective carbon  
21 atom at position 5 of the pyrazole ring and the protons at the *ortho* position of the  
22 fluorinated phenyl ring. A correlation was also observed between the aforementioned  
23 carbon and the protons of the methylene group attached to the cyclohexyl ring  
24 (Figure 7A). As far as 3,5-AB-CHMFUPPYCA was concerned, the 3-bond correlation  
25 between the carbon atom at position 5 of the pyrazole ring and the protons on the  
26 methylene group attached to the cyclohexyl ring (Figure 7B) was also present. As  
27 expected, the 3-bond correlation with the protons on the fluorinated phenyl ring was  
28 not detected. The vendor sample was also subjected to HMBC analysis and  
29 confirmed the 3,5-AB-CHMFUPPYCA assignment (supplemental data). Further  
30 information was obtained from nuclear Overhauser effect spectroscopy (NOESY),  
31 which provided additional insights into distinguishing features between the two  
32 isomers. A qualitative nuclear Overhauser experiment (NOE) showed connectivity  
33 between the methylene group attached to the cyclohexyl ring and the protons  
34 attached to the *ortho* position of the fluorinated phenyl ring present in the 5,3-AB-  
35 CHMFUPPYCA isomer. This nOe was not observed with 3,5-AB-CHMFUPPYCA  
36 (supplemental data).  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47

#### 48 49 50 51 *X-Ray crystallography*

52  
53 The solid-state structure of the 3,5-AB-CHMFUPPYCA isomer was elucidated by  
54 single crystal X-ray diffraction and is shown below in Figure 8. The structure is a  
55 solvate with a co-crystallized molecule of acetonitrile present in the asymmetric unit.  
56 The molecule crystallizes in the chiral monoclinic space group  $P2_1$  and the chiral  
57  
58  
59  
60

center C22 has been determined to be the S-enantiomer. The packing is dominated by the amide donor groups (N21, N28), which form hydrogen bonds with the terminal amido oxygen O27 (N28...O27 range 2.856(2) - 2.963(2) Å). These link the molecules into a strongly associated chain. A channel exists between the chains and the acetonitrile solvent molecules lies within it. A weak NH...N interaction (N28...N29, 3.039 Å) exists between 3,5-AB-CHMFUPPYCA and the solvent (supplemental information).

## Conclusion

An in-depth analytical characterization of a 'research chemical' advertised as AZ-037 revealed mislabeling when it transpired that it was consistent with 3,5-AB-CHMFUPPYCA instead. The combination of analytical techniques and confirmation of compound identification by organic synthesis provided an effective approach to tackling an increasingly complex area of investigation where increasing demands are placed on investigators in the field of new psychoactive substances.

## References

- [1] S.D. Brandt, L.A. King, M. Evans-Brown. The new drug phenomenon. *Drug Test. Anal.* **2014**, *6*, 587.
- [2] European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). New psychoactive substances in Europe. An update from the EU Early Warning System (March 2015). Lisbon. **2015**. Available at: [http://www.emcdda.europa.eu/attachements.cfm/att\\_235958\\_EN\\_TD04\\_15135ENN.pdf](http://www.emcdda.europa.eu/attachements.cfm/att_235958_EN_TD04_15135ENN.pdf) [13 June 2015].
- [3] European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). European Drug Report. Trends and Developments. Lisbon. **2015**. Available at: [http://www.emcdda.europa.eu/attachements.cfm/att\\_239505\\_EN\\_TDAT\\_15001ENN.pdf](http://www.emcdda.europa.eu/attachements.cfm/att_239505_EN_TDAT_15001ENN.pdf) [13 June 2015].

- 1  
2  
3 [4] H. Chung, H. Choi, S. Heo, E. Kim, J. Lee. Synthetic cannabinoids abused in  
4 South Korea: drug identifications by the National Forensic Service from 2009  
5 to June 2013. *Forensic Toxicol.* **2014**, 32, 82.  
6  
7 [5] R. Kikura-Hanajiri, N. Uchiyama, M. Kawamura, Y. Goda. Changes in the  
8 prevalence of new psychoactive substances before and after the introduction  
9 of the generic scheduling of synthetic cannabinoids in Japan. *Drug Test. Anal.*  
10 **2014**, 6, 832.  
11  
12 [6] N. Uchiyama, S. Matsuda, M. Kawamura, R. Kikura-Hanajiri, Y. Goda. Two  
13 new-type cannabimimetic quinolinyl carboxylates, QUPIC and QUCHIC, two  
14 new cannabimimetic carboxamide derivatives, ADB-FUBINACA and ADBICA,  
15 and five synthetic cannabinoids detected with a thiophene derivative  $\alpha$ -PVT  
16 and an opioid receptor agonist AH-7921 identified in illegal products. *Forensic*  
17 *Toxicol.* **2013**, 31, 223.  
18  
19 [7] N. Uchiyama, S. Matsuda, D. Wakana, R. Kikura-Hanajiri, Y. Goda. New  
20 cannabimimetic indazole derivatives, N-(1-amino-3-methyl-1-oxobutan-2-yl)-  
21 1-pentyl-1H-indazole-3-carboxamide (AB-PINACA) and N-(1-amino-3-methyl-  
22 1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide (AB-  
23 FUBINACA) identified as designer drugs in illegal products. *Forensic Toxicol.*  
24 **2013**, 31, 93.  
25  
26 [8] G. Behonick, K.G. Shanks, D.J. Firchau, G. Mathur, C.F. Lynch, M.  
27 Nashelsky, D.J. Jaskierny, C. Meroueh. Four postmortem case reports with  
28 quantitative detection of the synthetic cannabinoid, 5F-PB-22. *J. Anal. Toxicol.*  
29 **2014**, 38, 559.  
30  
31 [9] T. Takayama, M. Suzuki, K. Todoroki, K. Inoue, J.Z. Min, R. Kikura-Hanajiri,  
32 Y. Goda, T. Toyo'oka. UPLC/ESI-MS/MS-based determination of metabolism  
33 of several new illicit drugs, ADB-FUBINACA, AB-FUBINACA, AB-PINACA,  
34 QUPIC, 5F-QUPIC and  $\alpha$ -PVT, by human liver microsome. **2014**, 28, 831.  
35  
36 [10] R. Thomsen, L.M. Nielsen, N.B. Holm, H.B. Rasmussen, K. Linnet. Synthetic  
37 cannabimimetic agents metabolized by carboxylesterases. *Drug Test. Anal.*  
38 **2014**,  
39  
40 [11] N. Uchiyama, Y. Shimokawa, M. Kawamura, R. Kikura-Hanajiri, T.  
41 Hakamatsuka. Chemical analysis of a benzofuran derivative, 2-(2-  
42 ethylaminopropyl)benzofuran (2-EAPB), eight synthetic cannabinoids, five  
43 cathinone derivatives, and five other designer drugs newly detected in illegal  
44 products. *Forensic Toxicol.* **2014**, 32, 266.  
45  
46 [12] M.S. Castaneto, A. Wohlfarth, S. Pang, M. Zhu, K.B. Scheidweiler, R.  
47 Kronstrand, M.A. Huestis. Identification of AB-FUBINACA metabolites in  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

- 1  
2  
3 human hepatocytes and urine using high-resolution mass spectrometry.  
4 *Forensic Toxicol.* **2015**, in press; doi: 10.1007/s11419.
- 5  
6 [13] C. Erratico, N. Negreira, H. Norouzizadeh, A. Covaci, H. Neels, K. Maudens,  
7 A.L. van Nuijs. In vitro and in vivo human metabolism of the synthetic  
8 cannabinoid AB-CHMINACA. *Drug Test. Anal.* **2015**, in press; doi:  
9 10.1002/dta.1796.
- 10  
11 [14] M.B. Gatch, M.J. Forster.  $\Delta^9$ -Tetrahydrocannabinol-like effects of novel  
12 synthetic cannabinoids found on the gray market. *Behav. Pharmacol.* **2015**, in  
13 press; doi: 10.1097/fbp.000000000000150.
- 14  
15 [15] K. Hasegawa, A. Wurita, K. Minakata, K. Gonmori, H. Nozawa, I. Yamagishi,  
16 K. Watanabe, O. Suzuki. Postmortem distribution of AB-CHMINACA, 5-fluoro-  
17 AMB, and diphenidine in body fluids and solid tissues in a fatal poisoning  
18 case: usefulness of adipose tissue for detection of the drugs in unchanged  
19 forms. *Forensic Toxicol.* **2015**, 33, 45.
- 20  
21 [16] K. Hasegawa, A. Wurita, K. Minakata, K. Gonmori, I. Yamagishi, H. Nozawa,  
22 K. Watanabe, O. Suzuki. Identification and quantitation of 5-fluoro-ADB, one  
23 of the most dangerous synthetic cannabinoids, in the stomach contents and  
24 solid tissues of a human cadaver and in some herbal products. *Forensic*  
25 *Toxicol.* **2015**, 33, 112.
- 26  
27 [17] M.D. Schwartz, J. Trecki, L.A. Edison, A.R. Steck, J.K. Arnold, R.R. Gerona.  
28 A common source outbreak of severe delirium associated with exposure to  
29 the novel synthetic cannabinoid ADB-PINACA. *J. Emerg. Med.* **2015**, 48, 573.
- 30  
31 [18] N. Uchiyama, Y. Shimokawa, R. Kikura-Hanajiri, Y. Demizu, Y. Goda, T.  
32 Hakamatsuka. A synthetic cannabinoid FDU-NNEI, two 2H-indazole isomers  
33 of synthetic cannabinoids AB-CHMINACA and NNEI indazole analog (MN-18),  
34 a phenethylamine derivative N-OH-EDMA, and a cathinone derivative  
35 dimethoxy- $\alpha$ -PHP, newly identified in illegal products. *Forensic Toxicol.* **2015**,  
36 1.
- 37  
38 [19] A. Wohlfarth, M.S. Castaneto, M. Zhu, S. Pang, K.B. Scheidweiler, R.  
39 Kronstrand, M.A. Huestis. Pentylindole/pentylindazole synthetic cannabinoids  
40 and their 5-fluoro analogs produce different primary metabolites: metabolite  
41 profiling for AB-PINACA and 5F-AB-PINACA. *AAPS J.* **2015**, 17, 660.
- 42  
43 [20] A. Wurita, K. Hasegawa, K. Minakata, K. Gonmori, H. Nozawa, I. Yamagishi,  
44 K. Watanabe, O. Suzuki. Identification and quantitation of 5-fluoro-ADB-  
45 PINACA and MAB-CHMINACA in dubious herbal products. *Forensic Toxicol.*  
46 **2015**, 1.
- 47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

- 1  
2  
3 [21] Drug Enforcement Administration, Department of Justice. Schedules of  
4 controlled substances: temporary placement of four synthetic cannabinoids  
5 into Schedule I. Final order. *Fed. Regist.* **2014**, *79*, 7577.  
6  
7 [22] Drug Enforcement Administration, Department of Justice. Schedules of  
8 controlled substances: temporary placement of three synthetic cannabinoids  
9 into Schedule I. Final order. *Fed. Regist.* **2015**, *80*, 5042.  
10  
11 [23] U. Girreser, P. Rösner, A. Vasilev. Structure elucidation of the designer drug  
12 N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(5-fluoropentyl)-3-(4-  
13 fluorophenyl)-pyrazole-5-carboxamide and the relevance of predicted C NMR  
14 shifts - a case study. *Drug Test. Anal.* **2015**, in press; doi: 10.1002/dta.1820.  
15  
16 [24] European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). Early-  
17 Warning-System on New Drugs. AB-CHMFUPPYCA. EMCDDA database on  
18 new drugs (EDND), 2015, restricted access.  
19  
20 [25] N. Uchiyama, K. Asakawa, R. Kikura-Hanajiri, T. Tsutsumi, T. Hakamatsuka.  
21 A new pyrazole-carboxamide type synthetic cannabinoid AB-CHFUPPYCA [N-  
22 (1-amino-3-methyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-3-(4-fluorophenyl)-  
23 1H-pyrazole-5-carboxamide] identified in illegal products. *Forensic Toxicol.*  
24 **2015**, in press; doi: 10.1007/s11419.  
25  
26 [26] L.M. Huppertz, S. Kneisel, V. Auwärter, J. Kempf. A comprehensive library-  
27 based, automated screening procedure for 46 synthetic cannabinoids in  
28 serum employing liquid chromatography-quadrupole ion trap mass  
29 spectrometry with high-temperature electrospray ionization. *J. Mass*  
30 *Spectrom.* **2014**, *49*, 117.  
31  
32 [27] L.A. King. Legal controls on cannabimimetics: an international dilemma? *Drug*  
33 *Test. Anal.* **2014**, *6*, 80.  
34  
35 [28] F. Westphal, F.D. Sönnichsen, S. Knecht, V. Auwärter, L. Huppertz. Two  
36 thiazolylindoles and a benzimidazole: novel compounds on the designer drug  
37 market with potential cannabinoid receptor activity. *Forensic Sci. Int.* **2015**,  
38 *249*, 133.  
39  
40 [29] I.P. Buchler, M.J. Hayes, S.G. Hedge, S.L. Hockerman, D.E. Jones, S.W.  
41 Kortum, J.G. Rico, R.E. Tenbrink, K.K. Wu. Indazole derivatives. Pfizer Inc.,  
42 USA. WO2009106982A1, **2009**.  
43  
44 [30] I.P. Buchler, M.J. Hayes, S.G. Hegde, S.L. Hockerman, D.E. Jones, S.W.  
45 Kortum, J.G. Rico, R.E. Tenbrink, K.K. Wu. Indazole derivatives. Pfizer Inc.,  
46 USA. WO2009106980A2, **2009**.  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

- 1  
2  
3 [31] European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). Early-  
4 Warning-System on New Drugs. 5F-AB-FUPPYCA. EMCDDA database on  
5 new drugs (EDND), **2015**, restricted access.  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For Peer Review

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Figures

**Figure 1.** Chemical structures of synthetic cannabinoids from (A) the PINACA, FUBINACA, CHMINACA series and (B) the FUPPYCA series.

**Figure 2.** Synthesis protocol for the AB-CHMFUPPYCA isomers. (A) Specific synthetic route for 5,3-AB-CHMFUPPYCA. (B) Specific synthetic route for 3,5-AB-CHMFUPPYCA.

**Figure 3.** (A-F) GC-MS data obtained for both AB-CHMFUPPYCA isomers and vendor sample. (G) Proposed EI-MS fragmentation patterns for the AB-CHMFUPPYCA isomers.



**Figure 4.** Proposed mechanism for the formation of 1-(cyclohexylmethyl)-3-(4-fluorophenyl)-1*H*-pyrazole species observed at  $m/z$  257 in the EI-mass spectrum of 3,5-AB-CHMFUPPYCA.

**Figure 5.** (A-F) Analysis of synthesized AB-CHMFUPPYCA isomers and vendor sample using high performance liquid chromatography selected ion monitoring (SIM) mass spectrometry at 50V.

**Figure 6.** (A-B) Electrospray ionization single quadrupole mass spectra following in-source collision-induced dissociation at 150 V. (C) Proposed mechanism for the formation of the species with  $m/z$  260 that may be rationalized by the loss of 2-cyclohexylacetamide from the protonated molecule.

**Figure 7.** Heteronuclear multiple-bond correlation NMR spectra for (A) the 5,3-AB-CHMFUPPYCA isomer and (B) the 3,5-AB-CHMFUPPYCA isomer.


**Figure 8.** Molecular structure of 3,5-AB-CHMFUPPYCA (thermal displacement at 50% probability) with hydrogen atoms omitted for clarity.



Chemical structures of synthetic cannabinoids from (A) the PINACA, FUBINACA, CHMINACA series and (B) the FUPPYCA series.

153x130mm (300 x 300 DPI)






Synthesis protocol for the AB-CHMFUPPYCA isomers. (A) Specific synthetic route for 5,3-AB-CHMFUPPYCA.


(B) Specific synthetic route for 3,5-AB-CHMFUPPYCA.

142x101mm (300 x 300 DPI)



(A-F) GC-MS data obtained for both AB-CHMFUPPYCA isomers and vendor sample. (G) Proposed EI-MS fragmentation patterns for the AB-CHMFUPPYCA isomers.

288x401mm (300 x 300 DPI)




20 Proposed mechanism for the formation of 1-(cyclohexylmethyl)-3-(4-fluorophenyl)-1H-pyrazole species  
21 observed at  $m/z$  257 in the EI-mass spectrum of 3,5-AB-CHMFUPPYCA.


22 66x24mm (300 x 300 DPI)

23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60


Peer Review




(A-F) Analysis of synthesized AB-CHMFUPPYCA isomers and vendor sample using high performance liquid chromatography selected ion monitoring (SIM) mass spectrometry at 50V.  
266x415mm (300 x 300 DPI)



(A-B) Electrospray ionization single quadrupole mass spectra following in-source collision-induced dissociation at 150 V. (C) Proposed mechanism for the formation of the species with  $m/z$  260 that may be rationalized by the loss of 2-cyclohexylacetamide from the protonated molecule.  
215x294mm (300 x 300 DPI)



Heteronuclear multiple-bond correlation NMR spectra for (A) the 5,3-AB-CHMFUPPYCA isomer and (B) the 3,5-AB-CHMFUPPYCA isomer.  
288x422mm (300 x 300 DPI)



Molecular structure of 3,5-AB-CHMFUPPYCA (thermal displacement at 50% probability) with hydrogen atoms omitted for clarity.

159x168mm (96 x 96 DPI)